Menu
Menu
Alembic Pharmaceuticals has secured USFDA approval for its generic version of Brexpiprazole Tablets, a treatment for major depressive disorder and schizophrenia. This approval opens the door to a $2 billion market, providing a more affordable option for patients while strengthening Alembic’s position in the generics sector.
Glenmark Pharmaceuticals has launched its Lacosamide Oral Solution, a bioequivalent to Vimpat® Oral Solution, offering a more affordable treatment option for partial-onset seizures. This new product enhances access to epilepsy care, with the same therapeutic efficacy as the branded version, making it a valuable option for patients and healthcare providers.
Strides Pharma Science Ltd's subsidiary has achieved a significant milestone with the USFDA’s approval of its generic Fluoxetine tablets (60 mg). This new approval opens doors for a cost-effective alternative to the branded antidepressant, enhancing patient access and strengthening Strides Pharma's presence in the competitive US generics market. Dive into the details of this important development and what it means for patients and the pharmaceutical industry.
Biocon Pharma has secured USFDA approval to market its generic Sacubitril/Valsartan Tablets, available in three strengths: 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg. This milestone is set to offer a cost-effective alternative for treating chronic heart failure, enhancing patient access and expanding Biocon’s market presence. Discover the significance of this approval and its implications for both patients and the pharmaceutical industry.
Zydus Lifesciences has achieved a major milestone with USFDA approval for Amantadine extended-release capsules, aimed at treating dyskinesia in Parkinson’s disease patients. The company has also received tentative approval for Gocovri capsules, promising more affordable treatment options. Discover how these approvals could enhance access to essential Parkinson's disease therapies.
In a pivotal development, Alembic Pharmaceuticals has secured tentative approval from the USFDA for their generic Selexipag injection, a crucial treatment for pulmonary arterial hypertension. This milestone not only underscores Alembic's commitment to healthcare innovation but also sets the stage for enhanced accessibility and affordability in critical medication.
Dive into the realm of affordable healthcare solutions with Glenmark's Generic Esomeprazole Magnesium, offering effective relief from acid-related discomforts at a fraction of the cost of branded alternatives. Explore the world of generic medications with Glenmark's Esomeprazole Magnesium, a trusted choice for individuals seeking relief from conditions triggered by excessive stomach acid production, now accessible with USFDA approval. Unlock the potential for cost-effective treatment options with Glenmark's Generic Esomeprazole Magnesium, designed to provide the same therapeutic benefits as branded medications, ensuring quality care for acid-related ailments. Embrace the promise of affordable healthcare with Glenmark's Generic Esomeprazole Magnesium, a testament to the company's commitment to delivering accessible medication options without compromising on quality or efficacy. Step into a realm of accessible relief with Glenmark's Esomeprazole Magnesium, FDA-approved and ready to address the discomforts associated with conditions stemming from excessive acid production in the stomach.